| Description |
HS-131, a near infrared dye tethered Hsp90 inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers[1].
|
| Related Catalog |
|
| In Vitro |
Immunofluorescence[1] Cell Line: Tumor cells. Concentration: 10 µM. Incubation Time: 30 min. Result: Tissues/organs, including eyes, brain, heart, lung, liver, spleen, kidney, gut, urinary bladder and skin, were imaged ex vivo by the IVIS imager machine, an imaging modality that detects IR at 640 nm.
|
| In Vivo |
HS131 (10 nmoL/mouse) could label breast cancers with different molecular subtypes, including MCF-7 and T-47D for luminal type, BT474M1 and KPL-4 for HER2+ subtype, MDA-MB-231 and MDA-MB-468 for triple negative subtype were chosen after considering the tumorigenic capacities of breast cancer cell lines in SCID mice[1]. Animal Model: SCID-beige mice bearing human breast cancer xenografts of different molecularsubtypes[1]. Dosage: 10 nmoL/mouse. Administration: Injected intravenously. Result: All breast cancer xenografts with different molecular subtypes showed stronger nIR signals in tumor by intravenous administration of HS131 compared to HS152, and the retention of the nIR signals was detectable even at the 24 h time point in HS131 injected mice.
|
| References |
[1]. Takuya Osada, et al. In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. Clin Cancer Res. 2017 Dec 15;23(24):7531-7542.
|
